IVD Test Procedure Volumes, 2024-2029

Table of Contents

Chapter One: Executive Summary

IVD Procedure Volume Estimate and Forecast

• Figure 1-1: Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)

Scope & Methodology

About Kalorama Information

Chapter Two: Introduction

Overview

Industry Trends

• Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
• Figure 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)

COVID-19

Demographic Trends

Global Population and Aging

• Figure 2-2: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
• Figure 2-3: Global Population Distribution, 2022
• Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)

Workforce Reduction

• Table 2-3: Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)

Increase in Chronic Diseases

• Figure 2-4: Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)

Personalized Medicine

New Infectious Disease Threats

• Table 2-4: Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats

Tickborne Diseases (TBDs)

Zika

Chagas

Dengue

Ebola

Chikungunya

Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)

Marburg

SARS-CoV-2 (COVID-19)

Monkeypox

• Table 2-5: Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox

Emerging and Emerged Markets

• Table 2-6: Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)

Chapter Three: IVD Testing Segments

IVD Testing Trends

• Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-2: IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-3: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-4: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-5: IVD Procedural Volume excluding Blood Glucose Tests, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-6: IVD Procedural Volume excluding Blood Glucose Tests, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-7: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-8: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)

Segment Growth Projections

POC Testing

• Table 3-5: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
• Figure 3-9: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)

Clinical Chemistry

• Table 3-6: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-10: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Immunoassays

• Table 3-7: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-11: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Mass Spectrometry (Immuno)

• Table 3-8: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-12: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Molecular Assays

• Table 3-9: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-13: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Hematology

• Table 3-10: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-14: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Coagulation

• Table 3-11: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-15: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Conventional Microbiology

• Table 3-12: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-16: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Blood Grouping/Typing

• Table 3-13: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-17: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Histology/Cytology

• Table 3-14: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Figure 3-18: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)

Segment Product Sales

• Table 3-15: IVD Product Sales including Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-19: IVD Product Sales including Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-20: IVD Product Sales including Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Table 3-16: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-21: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-22: IVD Product Sales including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Table 3-17: IVD Product Sales excluding Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-23: IVD Product Sales excluding Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-24: IVD Product Sales excluding Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Table 3-18: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-25: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Figure 3-26: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)

Chapter Four: Global IVD Markets

General

• Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, & South America; Middle East; North America [United States; Canada]; Western Europe)
• Figure 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
• Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
• Figure 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)

North America

• Table 4-3: North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
• Figure 4-3: North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)

United States

Canada

Mexico, Central & South America

• Table 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
• Figure 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)

Brazil

Mexico

Other Central & South America

• Argentina
• Chile
• Colombia
• Peru
• Venezuela
• All Other Countries & Territories

Western Europe

• Table 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
• Figure 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)

France

Germany

Italy

Spain

United Kingdom

Other Western Europe

• Austria
• Belgium
• Denmark
• Finland
• Greece
• Ireland
• Norway
• Netherlands
• Portugal
• Sweden
• Switzerland
• All Other Countries & Territories

Eastern Europe

• Table 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
• Figure 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)

Russia

Other Eastern Europe

• Czech Republic
• Hungary
• Poland
• Romania
• Ukraine
• All Other Countries

Asia/Pacific

• Table 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
• Figure 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)

China

Japan

Other Asian Countries and Territories

• Australia
• Hong Kong
• India
• Indonesia
• Malaysia
• Pakistan
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• New Zealand
• All Other Countries & Territories

Middle East

• Table 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
• Figure 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)

Turkey

Other Middle East

• Iran
• Iraq
• Israel
• Saudi Arabia
• United Arab Emirates
• All Other Countries

Africa

• Table 4-9: Africa IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
• Figure 4-9: Africa IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
• Nigeria
• South Africa
• All Other Countries & Territories

Chapter Five: Point-of-Care (POC) Procedures

Global POC Procedure Volume by Test Type

• Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2024-2029
• Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2024-2029
• Figure 5-1: Regional POC Procedure Volumes excluding blood glucose tests, 2024 (Europe, Japan, United States, Rest of World)

POC Self Tests

• Table 5-3: POC Self-Test Procedural Volume, by Type, 2024-2029 (millions) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])

Traditional Blood Glucose Monitoring Activities

Continuous Blood Glucose Monitoring

Pregnancy and Fertility Testing

Coagulation Testing

Fecal Occult Blood Testing

Drugs of Abuse Testing

1. Pylori Testing

HIV Testing

Infectious Disease

Cholesterol Testing

POC Urinalysis Testing

Other POC Self-Testing

POC Self-Testing Product Sales

• Table 5-4: POC Self-Test Product Sales, by Type, 2024-2029 ($ million) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])

Pricing Trends

• Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2024-2029 (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])

POC Professional Testing

• Table 5-6: POC Professional Procedural Volume, by Type, 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)

POC Professional Blood Glucose Testing Procedures

POC Professional Critical Care Testing

POC Fertility Testing

POC Professional Infectious Disease Testing

POC Professional Cardiac Marker Testing

POC Professional Cholesterol/Lipid Testing

POC Professional Coagulation Testing

POC Professional HbA1C Testing

POC Professional Hematology Testing

POC Professional Fecal Occult Blood Screening

POC Professional Drugs of Abuse Testing

POC Professional Urinalysis Testing

Other POC Professional Testing

POC IVD Product Sales

• Table 5-7: POC Professional IVD Product Sales, by Type, 2024-2029 ($ million) (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)

Pricing Trends

• Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)

Chapter Six: Clinical Chemistry Procedures

• Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2024-2029 (Blood Gas Analysis, General Chemistry, Urinalysis)
• Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)

Types of Tests

General Chemistry

• Enzymes
• Glucose
• Lipids
• Proteins
• Other Compounds

Blood Gases & Electrolytes

Urinalysis

Global Sales of Clinical Chemistry Products

• Table 6-2: Clinical Chemistry Product Sales, by Type, 2024-2029 ($ million) (Blood Gas Analysis; General Chemistry; Urinalysis)

Pricing Trends

• Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2024-2029 (Blood Gas Analysis; General Chemistry; Urinalysis)

Chapter Seven: Immunoassay Procedures

Technologies

Labeling Techniques

Enzyme Immunoassays

Fluorescence Polarization Immunoassays (FPIAs)

Radioimmunoassays (RIAs)

• Table 7-1: Immunoassay Procedural Volume, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
• Figure 7-1: Regional Immunoassay Procedure Volumes, 2024

Testing Procedures & Product Sales

• Table 7-2: Immunoassay Product Sales, by Type, 2024-2029 ($ million) (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)

Cardiac Markers

Tumor Markers

Autoimmune Conditions

Allergy Conditions

Thyroid Conditions

Proteins

• Alzheimer’s Disease

Anemia

Fertility Testing

Therapeutic Drug Monitoring

Vitamin D

Diabetes/HbA1c

Drugs of Abuse

Infectious Diseases

• Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2024-2029 (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
• Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)

Instruments

Pricing Trends

• Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)

Chapter Eight: Molecular Testing Procedures

• Table 8-1: Molecular Assay Procedural Volume, by Type, 2024-2029 (millions) (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
• Figure 8-1: Regional Molecular Assay Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)

Types of Tests

Testing Technologies

Infectious Diseases

• Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2024-2029 (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)

Blood Screening

Cancer

Transplant Matching

Thrombophilia SNPs

Inherited Diseases

Other Molecular Tests

Prenatal

Global Sales of Molecular IVD Products

• Table 8-3: Molecular Assay Product Sales, by Type, 2024-2029 ($ million) (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
• Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)

Pricing Trends

• Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2024-2029 (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)

Chapter Nine: Laboratory-Based Hematology Procedures

• Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2024-2029 (Complete Blood Count; Other Hematology Tests)
• Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)

Types of Tests

Global Sales of Hematology Products

• Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2024-2029 ($ million) (Complete Blood Count; Other Hematology Tests)

Pricing Trends

• Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2024-2029 (Complete Blood Count, Other Hematology Tests)

Chapter Ten: Coagulation Testing Procedures

• Table 10-1: Coagulation Procedural Volume, 2024-2029 (D-dimer, PT/INR)
• Figure 10-1: US/ROW Coagulation Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)

Types of Tests

Global Sales of Coagulation Products

• Table 10-2: Coagulation Product Sales, 2024-2029 ($ million) (D-dimer, PT/INR)

Pricing Trends

• Table 10-3: Coagulation $ Products per Procedure, 2024-2029 (D-dimer, PT/INR)

Chapter Eleven: Microbiology Procedures

• Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
• Figure 11-1: Regional Microbiology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)

Types of Tests

ID/AST Automated Panels & Reagents

Manual Panels & Reagents

Blood Culture

Chromogenic Media

Rapid Microbiological Tests

Mass Spectrometry

Global Sales of Conventional IVD Microbiology Products

ID/AST Panels & Reagents

Blood Culture

Chromogenic Media

Rapid Microbiological Tests

Mass Spectrometry

• Table 11-2: Conventional Microbiology Product Sales, by Type, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)

Pricing Trends

• Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2024-2029
• (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)

Chapter Twelve: Blood Grouping/Typing Procedures

• Table 12-1: Blood Grouping/Typing Procedure Volumes, 2024-2029
• Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)

Types of Tests

Blood Grouping/Typing Product Sales

• Table 12-2: Blood Grouping/Typing Product Sales, 2024-2029 ($ million)

Pricing Trends

• Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2024-2029

Chapter Thirteen: Histology/Cytology Procedures

• Table 13-1: Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
• Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)

Types of Tests

Immunohistochemistry Tests

In Situ Hybridization Tests

Pap Tests

Traditional Non-Pap Stains

Circulating Tumor Cells

Flow Cytometry

Histology/Cytology IVD Product Sales

• Table 13-2: Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)

Pricing Trends

• Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029

Chapter Fourteen: Company Profiles

• Table 14-1: Revenues of Selected Top 20 IVD Companies, 2023 and estimated 2024 ($ million) (Abbott Diagnostics; Agilent; Becton Dickinson; bioMérieux; Bio-Rad Laboratories; Bruker – CALID; Danaher; Dexcom; DiaSorin; Exact Sciences; Hologic; Illumina; Natera; QuidelOrtho; Revvity; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Thermo Fisher Scientific; Werfen)

Abbott Diagnostics

Recent Revenue History

• Table 14-2: Abbott Diagnostic Revenues, 2017-2023 (million $)

Core Lab

Hematology

Blood Banking

Infectious Diseases – Molecular

Diabetes

HIV Point of Care

i-STAT Business

COVID-19

Agilent Technologies

Recent Revenue History

• Table 14-3: Agilent Revenues, 2017-2023 (million $)

Agilent in Genomics

Cytogenetic Analysis

Sequencing

Flow Cytometry

Companion Diagnostics – Dako

COVID-19

Becton, Dickinson and Company (BD)

Recent Revenue History

• Table 14-4: BD Diagnostic Revenues, 2017-2023 (million $) FYE Sept 30

Cytology

Molecular Microbiology

Traditional Microbiology – ID/AST

Blood Culture

Hospital Acquired Infections

Blood Collection

Mass Spectrometry

COVID-19

bioMérieux Inc.

Recent Revenue History

• Table 14-5: bioMérieux IVD Revenues, 2017-2023 (million $)

Traditional Microbiology

Blood Culture

Immunoassays

Mass Spectrometry

BioFire Diagnostics Business

COVID-19

Bio-Rad Laboratories, Inc.

Recent Revenue History

• Table 14-6: Bio-Rad Diagnostics Revenues, 2017-2023 (million $)

Blood Bank

Immunoassays

COVID-19

Bruker Corporation

Recent Revenue History

• Table 14-7: Bruker Revenue History Product Revenue, 2017-2023 ($ million)

Acquisitions and Collaborations

Mass Spectrometry

Microbiology

Molecular PCR

COVID-19

Danaher Corporation

Recent Revenue History

• Table 14-8: Danaher Global IVD Diagnostic Sales, 2017-2023 (million $)

Dexcom

Recent Revenue History

• Table 14-9: Dexcom IVD Diagnostic Sales, 2017-2023 (million $)

DiaSorin

Recent Revenue History

• Table 14-10: DiaSorin Revenues, 2017-2023 (million $)

Immunoassays

Molecular

COVID-19

Exact Sciences

Recent Revenue History

• Table 14-11: Exact Sciences Revenues, 2017-2023 (million $)

COVID-19

Hologic, Inc.

Recent Revenue History

• Table 14-12: Hologic Revenues, 2017-2023 (million $)

PANTHER Molecular System

HIV Testing

Sexually Transmitted Infections

Infectious Diseases

Cytology

COVID-19

Illumina

Recent Revenue History

• Table 14-13: Illumina Diagnostics Revenues, 2017-2023 (million $)

COVID-19

Instrument Laboratory/ Werfen

Expansion

Coagulation

Acute Care

Natera

Recent Revenue History

• Table 14-14: Natera Revenue History 2017-2023 ($ million)

Prenatal Paternity Testing

QuidelOrtho Corporation

Recent Revenue History

• Table 14-15: QuidelOrtho Revenue History 2018-2023 ($ million)

Immunoassays

Rapid Immunoassays

The Solana Business

Molecular – Savanna

Blood Bank

COVID-19

Revvity

• Table 14-16: Revvity Revenue History 2021-2023 ($ million, estimated)

Roche Diagnostics

Recent Revenue History

• Table 14-17: Roche Diagnostics IVD Revenues, 2017-2023 (million $)

Hematology

Core Lab

Immunoassays

HIV

Core Molecular

Digital PCR

Diabetes Care

Coagulation

cobas Liat System – POC

HPV

Blood Bank

Transplant Medicine

Cancer Companion Testing

COVID-19

Siemens Healthineers (Siemens)

Recent Revenue History

• Table 14-18: Siemens Healthineers IVD Revenues, 2017-2023 (million $)

Immunoassays

Hematology

Molecular

Acute Care – POC

COVID-19

Sysmex Corporation

Recent Revenue History

• Table 14-19: Sysmex IVD Revenues 2018-2023 (million $) FY March 31

Hematology

Coagulation

Urinalysis

Immunoassays

Precision Medicine / Companion Test Diagnostics

Oncology

COVID-19

Thermo Fisher Scientific Inc.

Recent Revenue History

• Table 14-20: Thermo Fischer IVD Revenues, 2017-2023 (million $)

Immunoassays

Microbiology

Next Generation Sequencing

Molecular and qPCR

Mass Spectrometry

COVID-19

Werfen

Recent Revenue History

• Table 14-21: Werfen IVD Revenues, 2017-2023 (million $)

Hematology and Coagulation

Autoimmunity